Cargando…

Searching for a technology-driven acute rheumatic fever test: the START study protocol

INTRODUCTION: The absence of a diagnostic test for acute rheumatic fever (ARF) is a major impediment in managing this serious childhood condition. ARF is an autoimmune condition triggered by infection with group A Streptococcus. It is the precursor to rheumatic heart disease (RHD), a leading cause o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ralph, Anna P, Webb, Rachel, Moreland, Nicole J, McGregor, Reuben, Bosco, Anthony, Broadhurst, David, Lassmann, Timo, Barnett, Timothy C, Benothman, Rym, Yan, Jennifer, Remenyi, Bo, Bennett, Julie, Wilson, Nigel, Mayo, Mark, Pearson, Glenn, Kollmann, Tobias, Carapetis, Jonathan R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444258/
https://www.ncbi.nlm.nih.gov/pubmed/34526345
http://dx.doi.org/10.1136/bmjopen-2021-053720
_version_ 1784568452662427648
author Ralph, Anna P
Webb, Rachel
Moreland, Nicole J
McGregor, Reuben
Bosco, Anthony
Broadhurst, David
Lassmann, Timo
Barnett, Timothy C
Benothman, Rym
Yan, Jennifer
Remenyi, Bo
Bennett, Julie
Wilson, Nigel
Mayo, Mark
Pearson, Glenn
Kollmann, Tobias
Carapetis, Jonathan R
author_facet Ralph, Anna P
Webb, Rachel
Moreland, Nicole J
McGregor, Reuben
Bosco, Anthony
Broadhurst, David
Lassmann, Timo
Barnett, Timothy C
Benothman, Rym
Yan, Jennifer
Remenyi, Bo
Bennett, Julie
Wilson, Nigel
Mayo, Mark
Pearson, Glenn
Kollmann, Tobias
Carapetis, Jonathan R
author_sort Ralph, Anna P
collection PubMed
description INTRODUCTION: The absence of a diagnostic test for acute rheumatic fever (ARF) is a major impediment in managing this serious childhood condition. ARF is an autoimmune condition triggered by infection with group A Streptococcus. It is the precursor to rheumatic heart disease (RHD), a leading cause of health inequity and premature mortality for Indigenous peoples of Australia, New Zealand and internationally. METHODS AND ANALYSIS: ‘Searching for a Technology-Driven Acute Rheumatic Fever Test’ (START) is a biomarker discovery study that aims to detect and test a biomarker signature that distinguishes ARF cases from non-ARF, and use systems biology and serology to better understand ARF pathogenesis. Eligible participants with ARF diagnosed by an expert clinical panel according to the 2015 Revised Jones Criteria, aged 5–30 years, will be recruited from three hospitals in Australia and New Zealand. Age, sex and ethnicity-matched individuals who are healthy or have non-ARF acute diagnoses or RHD, will be recruited as controls. In the discovery cohort, blood samples collected at baseline, and during convalescence in a subset, will be interrogated by comprehensive profiling to generate possible diagnostic biomarker signatures. A biomarker validation cohort will subsequently be used to test promising combinations of biomarkers. By defining the first biomarker signatures able to discriminate between ARF and other clinical conditions, the START study has the potential to transform the approach to ARF diagnosis and RHD prevention. ETHICS AND DISSEMINATION: The study has approval from the Northern Territory Department of Health and Menzies School of Health Research ethics committee and the New Zealand Health and Disability Ethics Committee. It will be conducted according to ethical standards for research involving Indigenous Australians and New Zealand Māori and Pacific Peoples. Indigenous investigators and governance groups will provide oversight of study processes and advise on cultural matters.
format Online
Article
Text
id pubmed-8444258
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84442582021-10-01 Searching for a technology-driven acute rheumatic fever test: the START study protocol Ralph, Anna P Webb, Rachel Moreland, Nicole J McGregor, Reuben Bosco, Anthony Broadhurst, David Lassmann, Timo Barnett, Timothy C Benothman, Rym Yan, Jennifer Remenyi, Bo Bennett, Julie Wilson, Nigel Mayo, Mark Pearson, Glenn Kollmann, Tobias Carapetis, Jonathan R BMJ Open Global Health INTRODUCTION: The absence of a diagnostic test for acute rheumatic fever (ARF) is a major impediment in managing this serious childhood condition. ARF is an autoimmune condition triggered by infection with group A Streptococcus. It is the precursor to rheumatic heart disease (RHD), a leading cause of health inequity and premature mortality for Indigenous peoples of Australia, New Zealand and internationally. METHODS AND ANALYSIS: ‘Searching for a Technology-Driven Acute Rheumatic Fever Test’ (START) is a biomarker discovery study that aims to detect and test a biomarker signature that distinguishes ARF cases from non-ARF, and use systems biology and serology to better understand ARF pathogenesis. Eligible participants with ARF diagnosed by an expert clinical panel according to the 2015 Revised Jones Criteria, aged 5–30 years, will be recruited from three hospitals in Australia and New Zealand. Age, sex and ethnicity-matched individuals who are healthy or have non-ARF acute diagnoses or RHD, will be recruited as controls. In the discovery cohort, blood samples collected at baseline, and during convalescence in a subset, will be interrogated by comprehensive profiling to generate possible diagnostic biomarker signatures. A biomarker validation cohort will subsequently be used to test promising combinations of biomarkers. By defining the first biomarker signatures able to discriminate between ARF and other clinical conditions, the START study has the potential to transform the approach to ARF diagnosis and RHD prevention. ETHICS AND DISSEMINATION: The study has approval from the Northern Territory Department of Health and Menzies School of Health Research ethics committee and the New Zealand Health and Disability Ethics Committee. It will be conducted according to ethical standards for research involving Indigenous Australians and New Zealand Māori and Pacific Peoples. Indigenous investigators and governance groups will provide oversight of study processes and advise on cultural matters. BMJ Publishing Group 2021-09-15 /pmc/articles/PMC8444258/ /pubmed/34526345 http://dx.doi.org/10.1136/bmjopen-2021-053720 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Global Health
Ralph, Anna P
Webb, Rachel
Moreland, Nicole J
McGregor, Reuben
Bosco, Anthony
Broadhurst, David
Lassmann, Timo
Barnett, Timothy C
Benothman, Rym
Yan, Jennifer
Remenyi, Bo
Bennett, Julie
Wilson, Nigel
Mayo, Mark
Pearson, Glenn
Kollmann, Tobias
Carapetis, Jonathan R
Searching for a technology-driven acute rheumatic fever test: the START study protocol
title Searching for a technology-driven acute rheumatic fever test: the START study protocol
title_full Searching for a technology-driven acute rheumatic fever test: the START study protocol
title_fullStr Searching for a technology-driven acute rheumatic fever test: the START study protocol
title_full_unstemmed Searching for a technology-driven acute rheumatic fever test: the START study protocol
title_short Searching for a technology-driven acute rheumatic fever test: the START study protocol
title_sort searching for a technology-driven acute rheumatic fever test: the start study protocol
topic Global Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444258/
https://www.ncbi.nlm.nih.gov/pubmed/34526345
http://dx.doi.org/10.1136/bmjopen-2021-053720
work_keys_str_mv AT ralphannap searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT webbrachel searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT morelandnicolej searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT mcgregorreuben searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT boscoanthony searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT broadhurstdavid searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT lassmanntimo searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT barnetttimothyc searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT benothmanrym searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT yanjennifer searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT remenyibo searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT bennettjulie searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT wilsonnigel searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT mayomark searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT pearsonglenn searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT kollmanntobias searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol
AT carapetisjonathanr searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol